

# **RHINOMED 2020 ANNUAL GENERAL MEETING**

## **RESULTS**

### **20 November 2020 Melbourne, Australia.**

Rhinomed Limited (ASX:RNO OTCQB:RHNMF) (**Rhinomed**), a leader in nasal airway and respiratory technology, announces the results of today's Annual General Meeting.

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, Rhinomed advises the results of the Annual General Meeting held today, 20 November 2020, which are set out in the attached document detailing all of the resolutions and proxies received in respect of each resolution.

All resolutions were passed and decided by way of poll.

This announcement has been authorised for release by the Board.

### **Media Enquiries**

Michael Johnson, CEO & Director

+61 (03) 8416 0900

[mjohnson@rhinomed.global](mailto:mjohnson@rhinomed.global)

Follow us on **Twitter** @rhinomedceo and @theturbinecom

Rudi Michelson, Monsoon Communications

+61 (0)411 402 737

[rudim@monsoon.com.au](mailto:rudim@monsoon.com.au)

### **About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)**

Rhinomed Limited is a Melbourne-based ASX-listed airway technology company that has developed a novel nasal and respiratory technology platform.

With its initial product Turbine, Rhinomed has established a leading position in emphasizing the role of breathing in sport and exercise. With its Mute variant, the company has also entered the sleep sector to tackle the global snoring market, while its third product, the Pronto range, tackles nasal congestion and sleep disturbance issues. The company is developing applications for the delivery of medical cannabis and for conditions including anxiety, pain, allergies, nausea, anxiety and coughs and colds.

Rhinomed's devices are sold in over 20,000 stores worldwide including Walgreens, CVS, Boots and online with Amazon; and are approved in major markets including the US, Europe, Canada and Australia.

# Disclosure of Proxy Votes

## Rhinomed Limited

Annual General Meeting

Friday, 20 November 2020



**Automic**

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Adoption of Remuneration Report	P	150,912,468	145,106,763 96.15%	5,729,205 3.80%	0	76,500 0.05%	145,183,263 96.20%	5,729,205 3.80%	301,254
2 Re-election of Dr Eric Knight as a Director	P	164,412,468	158,763,713 96.56%	5,572,255 3.39%	0	76,500 0.05%	159,141,467 96.62%	5,572,255 3.38%	77,456
3 Approval of capacity to issue shares under ASX Listing Rule 7.1A	P	164,398,968	164,151,716 99.85%	170,752 0.10%	13,500	76,500 0.05%	164,606,926 99.90%	170,752 0.10%	13,500
4 Approval of Long Term Incentive Plan	P	150,909,968	145,021,763 96.10%	5,811,705 3.85%	2,500	76,500 0.05%	145,098,263 96.15%	5,811,705 3.85%	227,836
5 Approval of issue of options to Michael Johnson	P	164,409,968	158,422,470 96.36%	5,910,998 3.60%	2,500	76,500 0.05%	158,652,344 96.41%	5,910,998 3.59%	227,836
6 Ratification of Appointment of Auditor to fill vacancy	P	164,398,968	164,322,468 99.95%	0 0.00%	13,500	76,500 0.05%	164,777,678 100.00%	0 0.00%	13,500

